BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
日曜日, 9 13

Ocular Therapeutix Inc

OCULNASDAQ
Trade with Public
Trade with Public
$10.49
-0.13-1.22%
近くで: Sep 11, 5:00 PM EST
$10.69
0.201.91%
時間外: Sep 11, 7:44 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Ocular Therapeutix Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ocular Therapeutix (OCUL).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

2S.Buy
10Buy
Consensus RatingBuy# Analysts12Avg. Consensus PT$23Upside to Avg. PT+112.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Chardan CapitalAndreas ArgyridesMaintainedBuy$23
Jun 25, 2026Chardan CapitalAndreas ArgyridesPT RaiseBuy$21→$23
More with Benzinga EdgeGet Access

Analyst Ratings News

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
Vandana Singh

PRO
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23

Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $25.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30

Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target

RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and maintains $30 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $21 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $21 price target.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved